# 131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)

> **NCT07015684** · PHASE1 · RECRUITING · sponsor: **Columbia University** · enrollment: 24 (estimated)

## Conditions studied

- Sickling Disorder Due to Hemoglobin S

## Interventions

- **DRUG:** 131I-apamistmab
- **DRUG:** Sirolimus
- **DRUG:** Campath
- **DRUG:** Total Body Irradiation
- **PROCEDURE:** Exchange Transfusion
- **RADIATION:** Planar gamma imaging

## Key facts

- **NCT ID:** NCT07015684
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-28
- **Primary completion:** 2030-03-12
- **Final completion:** 2032-03-12
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07015684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07015684, "131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07015684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*